This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory
phase II dose-finding trial. The trial will be conducted with four treatment groups in the
form of a parallel group comparison and will serve to compare oral treatment with daily doses
of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with
fibrosis.